Company Overview
PROCEPT BioRobotics Corporation operates as a surgical robotics company focused on developing transformative solutions within the urology sector across the United States and internationally. The firm is dedicated to the development, manufacturing, and sale of the AquaBeam Robotic System, which serves as an image-guided, surgical robotic platform specifically designed for minimally invasive urologic surgery. This entity functions within the broader Healthcare sector and the specialized Medical Devices industry, where innovation in surgical technology drives market evolution. With a total market capitalization of $1.44B, an annual revenue of $308.05M, and a workforce of 888 employees, the company represents a significant player in its niche. These valuation and revenue figures indicate that the market assigns substantial worth to the company's proprietary robotic platform and its growth potential in the expanding minimally invasive surgery landscape.
Financial Health
The company reported revenue of $308.05M over the trailing twelve months, yet this generated a net income of -$95,572,000 and an EBITDA of -$97,469,000. The substantial gap between the positive revenue and the negative net income and EBITDA reveals a cost structure characterized by high operating expenses that exceed gross profits, likely due to research and development costs associated with advancing surgical robotics technology. Free cash flow stands at -$23,916,124, indicating that the company is currently burning cash to fund its operations and growth initiatives rather than generating surplus liquidity. This negative cash flow position suggests limited financial flexibility for immediate expansion without capital infusion, relying instead on existing cash reserves. The gross margin is 63.7%, which reflects the high pricing power and efficiency of the manufactured robotic systems before accounting for operational costs. In contrast, the operating margin is -40.6% and the profit margin is -31.0%, highlighting the significant pressure from overhead and R&D expenditures that have not yet been fully offset by scale. The company holds $286.50M in cash against $78.48M in debt, resulting in a debt-to-equity ratio of 21.45. Despite the high leverage ratio, the balance sheet appears fortified by the significant cash position, which provides a buffer against the negative earnings. The current ratio of 6.84 indicates a very strong short-term liquidity position, as the company possesses more than six times the assets required to cover its current liabilities. Return on equity is -24.9% and return on assets is -12.5%, metrics that reveal management is currently generating negative returns on the capital deployed, a common characteristic for high-growth medical device firms in the early commercialization phase.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -29.57. The difference between these metrics implies that the market is not valuing the company based on current profitability but rather on future expectations of earnings turnaround or cash flow generation. The price-to-book ratio is 3.94, which indicates that the market is pricing the company at nearly four times its book value, suggesting a premium assigned to its intangible assets and future growth prospects. Alternative valuation metrics such as the price-to-sales ratio of 4.69 and an EV/EBITDA of -12.79 further illustrate that investors are willing to pay a significant multiple of revenue despite the current lack of profitability. The stock has traded between a 52-week high of $66.85 and a 52-week low of $19.35. Assuming a current trading price within this range, the valuation fluctuates relative to the historical extremes, though the specific current price point is not provided in the available data. The beta value is 1.02, which means the stock exhibits volatility slightly higher than the broader market, moving in tandem with general market conditions while possessing its own unique risk profile. These valuation metrics collectively suggest a high-risk, high-reward profile typical of technology-driven medical device companies that have not yet achieved sustained profitability.
Growth & Income
Revenue growth year-over-year is 11.9%, demonstrating a solid expansion trajectory in the top line, while earnings growth is listed as N/A due to the company's current loss position. The fact that earnings growth is not available while revenue is growing implies that the company is prioritizing market share and product adoption over immediate profit maximization, a strategy common in the development of new surgical technologies. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute income to shareholders. Instead, the firm reinvests all of its earnings, or lack thereof, directly back into the business to fund research, development, and manufacturing capabilities. The overall growth and income profile is defined by strong double-digit revenue expansion funded by a robust cash balance, rather than by dividend income or consistent earnings growth. This approach aligns with a long-term strategy to transform the urology surgical landscape through technological innovation rather than providing immediate yield to investors.